Octavio Espinoza - 30 Jun 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Financial Officer
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Issuer symbol
LGND
Transactions as of
30 Jun 2025
Net transactions value
+$20,401
Form type
4
Filing time
02 Jul 2025, 19:32:09 UTC
Previous filing
13 May 2025
Next filing
09 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Espinoza Octavio Chief Financial Officer 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza 02 Jul 2025 0001905248

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Other $20,401 +224 +0.76% $91.08 29,852 30 Jun 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).